Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oligonucleotide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    110 result(s) found for: Oligonucleotide. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2012-000833-38 Sponsor Protocol Number: ISIS329993-CS6 Start Date*: 2012-06-19
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Phase 2 Study to Assess the Antiarrhythmic and Symptomatic Effect of the Second Generation Antisense Oligonucleotide ISIS 329993 Targeting CRP in Patients with Paroxysmal Atrial Fibrillation
    Medical condition: Atrial fibrillation (AF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004736-79 Sponsor Protocol Number: 1102-CT02 Start Date*: 2007-03-06
    Sponsor Name:Antisense Therapeutics Ltd.
    Full Title: A double-blind, placebo-controlled, randomised trial to prove the therapeutic concept and to determine the pharmacokinetic profile of ATL 1102 (VLA-4 antisense oligonucleotide) by subcutaneous inje...
    Medical condition: To evaluate the efficacy of a selected treatment regimen of ATL 1102 in patients with Relapsing Remitting MS (RRMS) inflammatory lesions using MRI with gadolinium administration compared to placebo.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2004-003813-18 Sponsor Protocol Number: C016 Start Date*: 2004-12-16
    Sponsor Name:Pfizer Inc
    Full Title: A continuation study of CPG 7909 Injection in patients with matastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy
    Medical condition: Patients with metastatic or recurrent malignancies who have stable disease or who have responded to CPG 7909 Injection therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-000327-27 Sponsor Protocol Number: ISIS396443-CS2 Start Date*: 2017-01-26
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: An Open-Label, Dose Escalation Study to Assess the Safety, Tolerability and Dose-Range Finding of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005388-33 Sponsor Protocol Number: GS101-P3-CG Start Date*: 2009-02-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A MULTICENTRE DOUBLE-BLIND RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND TOLERABILITY OF GS-101 EYE DROPS, AN ANTISENSE OLIGONUCLEOTIDE, VERSUS PLACEBO ON INHIBITION OF CORNEAL NEOVASCULARIZATIO...
    Medical condition: Patients with corneal neovascularization, a major risk factor of corneal graft rejection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed)
    Trial results: Removed from public view
    EudraCT Number: 2015-001924-40 Sponsor Protocol Number: GED-0301-CD-003 Start Date*: 2017-02-21
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 3, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of mongersen (GED-0301) for the treatment of adult and adolescent subjects with act...
    Medical condition: Active Crohn's disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000016693 10021315 Ileitis terminal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) GB (Prematurely Ended) CZ (Prematurely Ended) LV (Prematurely Ended) SK (Prematurely Ended) BE (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) GR (Prematurely Ended) FI (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) PL (Prematurely Ended) HR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000621-12 Sponsor Protocol Number: ISIS396443-CS3A Start Date*: 2017-02-15
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-002796-35 Sponsor Protocol Number: C4491011 Start Date*: 2021-01-07
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Vupanorsen (PF 07285557) in Statin-Treated Participan...
    Medical condition: dyslipidemia
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10058110 Dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: View results
    EudraCT Number: 2004-005015-29 Sponsor Protocol Number: GS101-P2-CG Start Date*: 2005-08-03
    Sponsor Name:Les Laboratoires CTRS
    Full Title: A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal ne...
    Medical condition: Patients suffering from keratitis or keratouveitits of infectious origin
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001836-72 Sponsor Protocol Number: ISIS416858-CS3 Start Date*: 2013-01-11
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Pati...
    Medical condition: Prophylaxis of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty (TKA)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-000493-35 Sponsor Protocol Number: ISIS-304801-CS17 Start Date*: 2016-02-17
    Sponsor Name:Akcea Therapeutics, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, with an Open Label Extension, Phase 2/3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Partial Lipodystrophy
    Medical condition: Partial lipodystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10053857 Partial lipodystrophy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) BE (Completed) PT (Prematurely Ended) ES (Completed) NL (Completed) GR (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002421-35 Sponsor Protocol Number: ISIS304801-CS6 Start Date*: 2014-10-27
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS)
    Medical condition: Familial Chylomicronemia Syndrome (FCS)
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10017339 Fredrickson Type I lipidaemia LLT
    18.1 100000004850 10060593 Fredrickson Type I lipidemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) IT (Completed) HU (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-003434-93 Sponsor Protocol Number: ISIS-304801-CS16 Start Date*: 2015-01-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of ISIS 304801 Administered Subcutaneously to Patients with Hypertriglyceridemia
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Ongoing) GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-000976-40 Sponsor Protocol Number: ION373-CS1 Start Date*: Information not available in EudraCT
    Sponsor Name:Ionis Pharmaceuticals, Inc
    Full Title: A Phase 1-3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION373 in Patients with Alexand...
    Medical condition: Alexander Disease
    Disease: Version SOC Term Classification Code Term Level
    22.1 10010331 - Congenital, familial and genetic disorders 10083059 Alexander disease PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001947-18 Sponsor Protocol Number: ISIS396443-CS4 Start Date*: 2015-07-07
    Sponsor Name:Ionis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Later-onset Spinal Muscula...
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) SE (Completed) ES (Completed) IT (Completed) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-004422-29 Sponsor Protocol Number: ISIS396443-CS3B Start Date*: 2014-11-13
    Sponsor Name:Isis Pharmaceuticals, Inc.
    Full Title: A Phase 3, Randomized, Double-blind, Sham-Procedure Controlled Study to Assess the Clinical Efficacy and Safety of ISIS 396443 Administered Intrathecally in Patients with Infantile-onset Spinal Mus...
    Medical condition: Spinal Muscular Atrophy (SMA)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) ES (Completed) SE (Completed) DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001294-23 Sponsor Protocol Number: 232SM303 Start Date*: Information not available in EudraCT
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam
    Medical condition: Muscular Atrophy, Spinal
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10041582 Spinal muscular atrophy PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) IT (Ongoing) ES (Prematurely Ended) DE (Ongoing) PL (Completed) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000462-21 Sponsor Protocol Number: 266-02/06 (AVT-02/2/PSO/02) Start Date*: 2008-01-15
    Sponsor Name:Avontec GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in the treatment of mild to mode...
    Medical condition: psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002765-31 Sponsor Protocol Number: 066-007/08 (AVT-02/2/PSO/03) Start Date*: 2008-06-18
    Sponsor Name:Avontec GmbH
    Full Title: A multicenter, randomized, double-blind, placebo-controlled, intraindividual-comparison phase IIa trial to evaluate the efficacy and safety of 2% AVT-02 UE ointment in an every other day treatment ...
    Medical condition: psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000164-28 Sponsor Protocol Number: 8400-201 Start Date*: 2013-04-04
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, 12-week Dose-Ranging Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10071117 Plaque psoriasis LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050577 Psoriatic plaque LLT
    14.1 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:11:46 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA